How big is the Asia-Pacific Insulin Delivery Devices Market?

NOV 2022: The Albanese Government is changing the lives of the 130,000 Australians with type 1 diabetes by subsidizing access to the next generation of Omnipod insulin pumps.
MAR 2022: Medtronic India announced the MiniMed 780G system launch in India. The MiniMed 780G system is a next-generation closed-loop insulin pump system for treating type 1 diabetes in people aged 7-80 years.

The Asia-Pacific Insulin Delivery Devices Market size is expected to reach USD 18.88 billion in 2024 and grow at a CAGR of greater than 2.68% to reach USD 21.55 billion by 2029. Read More

What is the current Asia-Pacific Insulin Delivery Devices Market size?

In 2024, the Asia-Pacific Insulin Delivery Devices Market size is expected to reach USD 18.88 billion. Read More

Who are the key players in Asia-Pacific Insulin Delivery Devices Market?

Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Company and Ypsomed Holding are the major companies operating in the Asia-Pacific Insulin Delivery Devices Market. Read More

What years does this Asia-Pacific Insulin Delivery Devices Market cover, and what was the market size in 2023?

In 2023, the Asia-Pacific Insulin Delivery Devices Market size was estimated at USD 18.39 billion. The report covers the Asia-Pacific Insulin Delivery Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia-Pacific Insulin Delivery Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Asia-Pacific Insulin Delivery Devices Companies

This report lists the top Asia-Pacific Insulin Delivery Devices companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Asia-Pacific Insulin Delivery Devices industry.